Similar Papers

Paper Title
Journal
Date
Author
Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial (S47.005)
Patricia Pozo-Rosich ... Emily Mccusker
Neurology | VOL. 100
Patricia Pozo-Rosich, et. al.Patricia Pozo-Rosich ... Emily Mccusker
25 Apr 2023
Effect of Eptinezumab on Utility Scores in Patients with Migraine: Results from the DELIVER Study (P13-12.011)
Linus Jonsson ... Susanne F Awad
Neurology | VOL. 100
Linus Jonsson, et. al.Linus Jonsson ... Susanne F Awad
25 Apr 2023
Structural equation modeling for identifying the drivers of health-related quality of life improvement experienced by patients with migraine receiving eptinezumab
Linus Jönsson ... Peter J Goadsby
The Journal of Headache and Pain | VOL. 25
Linus Jönsson, et. al.Linus Jönsson ... Peter J Goadsby
28 Mar 2024
Responder Rates With Eptinezumab Over 24 Weeks in Patients With Prior Migraine Preventive Treatment Failures (S47.007)
Messoud Ashina ... Jessica Ailani
Neurology | VOL. 100
Messoud Ashina, et. al.Messoud Ashina ... Jessica Ailani
25 Apr 2023
View more papers

More From: Neurology

Paper Title
Journal
Date
Author
Reader Response: Distribution of Silent Cerebral Infarcts in Adults With Sickle Cell Disease
Calixto Machado
Neurology | VOL. -
Calixto MachadoCalixto Machado
28 Jan 2025
Brain Hypertrophy in Patients With Mesial Temporal Lobe Epilepsy With Hippocampal Sclerosis and Its Clinical Correlates
Richard Zubal ... Marian Galovic
Neurology | VOL. 104
Richard Zubal, et. al.Richard Zubal ... Marian Galovic
28 Jan 2025
Reader Response: Wall-Eyed Bilateral Internuclear Ophthalmoplegia Variant Syndrome Caused by Isolated Left Thalamic Infarction.
Eric R Eggenberger
Neurology | VOL. 104
Eric R EggenbergerEric R Eggenberger
28 Jan 2025
Editors' Note: Distribution of Silent Cerebral Infarcts in Adults With Sickle Cell Disease
Aravind Ganesh ... Steven L Galetta
Neurology | VOL. -
Aravind Ganesh, et. al.Aravind Ganesh ... Steven L Galetta
28 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.